cere-110
Gene therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2004 (NCT00087789)
Timeline
Indications
Studied for
Mechanism of action
- Beta-nerve growth factorSupplementation
NGF supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cere-110
- cere-110
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00876863 | Phase 2 | Sep 1, 2009 | National Institute on Aging (NIA), Sangamo BioSciences |
| NCT00087789 | Phase 1 | Jun 1, 2004 | Ceregene |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ceregene | For profit | 1 | 1 | 1 | 2004 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2009 |
| Sangamo BioSciences | For profit | 1 | 1 | 1 | 2009 |
3 organizations
Page 1 / 1